RT Journal Article SR Electronic T1 Low-dose mitomycin C, etoposide, and cisplatin for invasive vulvar Paget's disease JF International Journal of Gynecologic Cancer JO Int J Gynecol Cancer FD BMJ Publishing Group Ltd SP 304 OP 307 DO 10.1136/ijgc-00009577-200205000-00011 VO 12 IS 3 A1 Y Watanabe A1 H Hoshiai A1 H Ueda A1 H Nakai A1 K Obata A1 K Noda YR 2002 UL http://ijgc.bmj.com/content/12/3/304.abstract AB Abstract. Watanabe Y, Hoshiai H, Ueda H, Nakai H, Obata K, Noda K. Low-dose mitomycin C, etoposide, and cisplatin for invasive Paget's disease.We report the effect of low-dose mitomycin C, etoposide, and cisplatin (low-dose MEP) therapy for three patients with invasive vulvar Paget's disease (invasive VPD) who declined radical vulvectomy and skin grafting. One patient achieved a complete response, while the other two showed partial responses (PR) without grade 3 or 4 adverse effects. The two patients with PR were undergone partial vulvectomy and inguinal lymph node dissection. All patients have no sign of recurrence for 10 months after chemotherapy. Our present results suggest that low-dose MEP is an effective and safe chemotherapy for invasive VPD and low-dose MEP may significantly improve postoperative quality of life in patients with invasive VPD by avoiding extensive vulvar resection and skin grafting.